特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アジアのワクチン市場予測(~2029年):共役ワクチン、不活化・サブユニットワクチン、弱毒化生ワクチン、組み換えワクチン、トキソイドワクチン、インフルエンザ、肝炎、ポリオ、髄膜炎菌、DTP、ロタウイルス、MMR、HPV

Asia Vaccines Market Forecast to 2029: Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV

発行 Visiongain Ltd 商品コード 917797
出版日 ページ情報 英文 178 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.75円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

アジアのワクチン市場予測(~2029年):共役ワクチン、不活化・サブユニットワクチン、弱毒化生ワクチン、組み換えワクチン、トキソイドワクチン、インフルエンザ、肝炎、ポリオ、髄膜炎菌、DTP、ロタウイルス、MMR、HPV Asia Vaccines Market Forecast to 2029: Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV
出版日: 2019年10月28日 ページ情報: 英文 178 Pages
概要

アジアのワクチン市場は2018年に70億米ドルになりました。今後CAGR8.8%で拡大すると見込まれています。日本のワクチン市場が2018年のアジアのワクチン市場の30%のシェアを有しています。

当レポートでは、アジアのワクチン市場について調査し、市場の動向と予測、市場規模、主要参入企業、国別動向についてまとめています。

第1章 報告書の概要

第2章 イントロダクション

  • ワクチンとは
  • ワクチンが予防する疾患
  • 市場促進因子と阻害因子
  • 機会

第3章 アジアのワクチン市場:2019~2029年

  • 世界ワクチン市場のシェアとしてのアジアのワクチン
  • 2018年の世界ワクチン市場
  • 2018年のアジアワクチン市場
  • セグメント別市場シェアは2029年までにどうなるか

第4章 ワクチン技術別市場

  • 主要技術
  • 共役ワクチン
  • 不活化・サブユニットワクチン
  • 弱毒化生ワクチン
  • 組み換えワクチン
  • トキソイドワクチン

第5章 適応別市場

  • 主な適応
  • インフルエンザ
  • 肝炎
  • ポリオ
  • 髄膜炎菌
  • DTP
  • ロタウイルス
  • MMR
  • HPV

第6章 国別市場

  • 主要国
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • ベトナム
  • フィリピン
  • タイ
  • インドネシア

第7章 企業プロファイル

第8章 結論

付録

図表

List of Tables

  • Table 2.1: Vaccines R&D in Asia
  • Table 3.1: Asia Vaccines Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 4.1: Asia Vaccines Market and Forecast by Vaccine Technology Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 4.2: Asia Conjugate Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 4.3: Asia Inactivated Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 4.4: Asia Live Attenuated Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 4.5: Asia Recombinant Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 4.6: Asia Toxoid Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.1: Asia Vaccines Market and Forecast by Indication Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.2: Asia Influenza Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.3: Asia Hepatitis Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.4: Asia Polio Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.5: Asia Meningococcal Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.6: Asia DTP Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.7: Asia Rotavirus Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.8: Asia MMR Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 5.9: Asia HPV Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.1: Asia Vaccines Market and Forecast, by Country Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.2: Japan Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.3: Japan Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4: Japan Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.5: China Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6: China Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.7: China Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.8: India Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.9: India Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.10: India Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.11: Australia Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.12: Australia Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.13: Australia Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.14: South Korea Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.15: South Korea Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.16: South Korea Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.17: Vietnam Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.18: Vietnam Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.19: Vietnam Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.20: Philippines Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.21: Philippines Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.22: Philippines Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.23: Thailand Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.24: Thailand Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.25: Thailand Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.26: Indonesia Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.27: Indonesia Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.28: Indonesia Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.1: Pipeline Analysis: Vaccines Market
  • Table 8.2: HIV Vaccine: Product Pipeline
  • Table 8.3: Malaria Vaccine: Product Pipeline

List of Figures

  • Figure 1.1: Asia Vaccines Market Segmentation Overview, 2018
  • Figure 2.1: History of Vaccine Development
  • Figure 2.2: Drivers & Restraints: Asia Vaccines Market
  • Figure 3.1: Global Vaccines Market Forecast: Revenues ($bn) and AGR (%), 2018-2029
  • Figure 3.2: Asia Vaccines Market Forecast: Revenues ($m) and AGR (%), 2018-2029
  • Figure 3.3: Asia Vaccines Market by Vaccine Technology: Market Shares (%), 2018 and 2029
  • Figure 3.4: Asia Vaccines Market by Indication: Market Shares (%), 2018 and 2029
  • Figure 3.5: Asia Vaccines Market by Country: Market Shares (%), 2018 and 2029
  • Figure 4.1: Asia Vaccines Market and Forecast: Revenues ($m) and AGR (%), 2018-2029
  • Figure 4.2: Asia Conjugate Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 4.3: Asia Inactivated Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 4.4: Asia Live Attenuated Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 4.5: Asia Recombinant Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 4.6: Asia Toxoid Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.1: Asia Vaccines Market and Forecast: Revenues ($m) and AGR (%), 2018-2029
  • Figure 5.2: Asia Influenza Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.3: Asia Hepatitis Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.4: Asia Polio Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.5: Asia Meningococcal Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.6: Asia DTP Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.7: Asia Rotavirus Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.8: Asia MMR Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 5.9: Asia HPV Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.1: Asia Vaccines Market and Forecast: Revenues ($m) and AGR (%), 2018-2029
  • Figure 6.2: Japan Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.3: China Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.4: India Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.5: Australia Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.6: South Korea Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.7: Vietnam Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.8: Philippines Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.9: Thailand Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 6.10: Indonesia Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029
  • Figure 8.1: Asia Vaccines Market Forecast: Revenues ($m) by Vaccine Technology, 2018-2029

List of Companies and Organisations Mentioned in the Report:

  • Afferent Pharmaceuticals
  • Affinivax, Inc.
  • Astellas Pharma
  • AstraZeneca
  • Bavarian Nordic
  • BIKEN Co. Ltd
  • Biological E. Limited
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BioNTech
  • Cancer Research UK
  • Chiba University
  • CSL, Ltd.
  • Daiichi Sankyo Company, Ltd.
  • Emergent Biosolutions, Inc.
  • European Commission
  • Ganymed Pharmaceuticals AG
  • GlaxoSmithKline
  • GlycoVaxyn AG
  • HitGen
  • Immunomic Therapeutics, Inc.
  • Inovio Pharmaceuticals
  • IOmet
  • Janssen
  • Johnson & Johnson
  • MedImmune
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna
  • Nanotherapeutics
  • Osaka University
  • Oswaldo Cruz Foundation
  • PaxVax
  • Pfizer
  • Potenza Therapeutics, Inc.
  • Protein Sciences
  • Sanofi
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceuticals Industries, Ltd.
  • Takeda
  • University of Oxford
  • University of Tokyo
  • Zydus Cadila
目次
Product Code: PHA0554

Title:
Asia Vaccines Market Forecast to 2029
Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV.

Asia vaccines market is estimated at $7bn in 2018 and is expected to grow at a CAGR of 8.8% during the first half of the forecast period. The Japanese vaccines market held 30% share of the Asian vaccines market in 2018.

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 178-page report you will receive 82 charts - all unavailable elsewhere.

The 178-page report provides clear detailed insight into the Asian vaccines market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Asia Vaccines Market revenue forecasts to 2029

Asia Vaccines Market revenue forecasts to 2029 by Vaccine Technology:

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines

Asia Vaccines Market revenue forecasts to 2029 by Indication:

  • Influenza
  • Hepatitis
  • Polio
  • Meningococcal
  • DTP
  • Rotavirus
  • MMR
  • HPV
  • Others

Asia Vaccines Market revenue forecasts to 2029 by Country:

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Vietnam
  • Philippines
  • Thailand
  • Indonesia
  • Rest of Asia

Further segmented by indication and vaccine technology.

Profiles of the selected leading companies:

  • Astellas
  • AstraZeneca
  • CSL, Ltd.
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceuticals Industries, Ltd.
  • Takeda

This report provides a Pipeline Analysis

This report discusses factors that drive and restrain the market. This report also discusses trends and opportunities in the market.

Key Questions Answered by this Report:

  • What is the current size of Asia vaccines market? How much will this market be worth from 2018 to 2029?
  • What are the main drivers and restraints that will shape Asia vaccines market over the next ten years?
  • What are the main segments within Asia vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why?
  • What factors will affect that industry and market over the next ten years?
  • What are the largest national markets for the Asian vaccines market? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2029?
  • Who are the leading companies and what are their activities, results, developments and prospects?

Visiongain's study is intended for anyone requiring commercial analyses for Asia Vaccines Market. You find data, trends and predictions.

Buy our report today Asia Vaccines Market Forecast to 2029: Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Asia Vaccines Market Overview
  • 1.2. Asia Vaccines Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Vaccines Market

  • 2.1. What are Vaccines?
  • 2.2. Diseases Vaccines Prevent
  • 2.3. Drivers and Challenges for the Asia Vaccines Market
    • 2.3.1. Drivers
      • 2.3.1.1. Growing demand in Asian region
      • 2.3.1.2. Rising geriatric population
      • 2.3.1.3. Increasing Population
      • 2.3.1.4. Growing Life Expectancy
    • 2.3.2. Restraints
      • 2.3.2.1. Funding difficult to sustain
  • 2.4. Opportunities

3. Asia Vaccines Market 2019-2029

  • 3.1. Asia Vaccines as a Share of the Global Vaccines Market
  • 3.2. The Global Vaccines Market in 2018
    • 3.2.1. Leading Companies in the Vaccines Market
  • 3.3. Asia Vaccines Market in 2018
  • 3.4. How Will Segmental Market Shares Change to 2029?

4. Asia Vaccines Market by Vaccine Technology 2018-2029

  • 4.1. Leading Vaccine Technologies in 2018
  • 4.2. Conjugate Vaccines
  • 4.3. Inactivated and Subunit Vaccines
  • 4.4. Live Attenuated Vaccines
  • 4.5. Recombinant Vaccines
  • 4.6. Toxoid Vaccines

5. Asia Vaccines Market by Indication 2018-2029

  • 5.1. Leading Indications in 2018
  • 5.2. Influenza
  • 5.3. Hepatitis
  • 5.4. Polio
  • 5.5. Meningococcal
  • 5.6. DTP
  • 5.7. Rotavirus
  • 5.8. MMR
  • 5.9. HPV

6. Asia Vaccines Market by Country 2018-2029

  • 6.1. Leading Countries in 2018
  • 6.2. Japan
    • 6.2.1. Vaccines in Japan
    • 6.2.2. Immunisation Program
    • 6.2.3. Vaccine Production
    • 6.2.4. Vaccine Regulation
  • 6.3. China
    • 6.3.1. Vaccines in China
    • 6.3.2. Vaccine Production
    • 6.3.3. Vaccine Regulations
  • 6.4. India
    • 6.4.1. Vaccination Schedule India
    • 6.4.2. Immunisation Program
    • 6.4.3. Vaccine Production
  • 6.5. Australia
    • 6.5.1. Vaccination Schedule Australia
    • 6.5.2. Immunisation Program
    • 6.5.3. Vaccine Regulation
  • 6.6. South Korea
    • 6.6.1. Vaccines in South Korea
    • 6.6.2. Immunisation Program
    • 6.6.3. South Korea Production
    • 6.6.4. South Korea Regulation
  • 6.7. Vietnam
    • 6.7.1. Vaccines in Vietnam
    • 6.7.2. Immunisation Program
    • 6.7.3. Vietnam Production
    • 6.7.4. Vietnam Regulations
  • 6.8. Philippines
    • 6.8.1. Vaccines in Philippines
    • 6.8.2. Immunisation Program
    • 6.8.3. Vaccine Production and Regulation
  • 6.9. Thailand
    • 6.9.1. Vaccines in Thailand
    • 6.9.2. Immunisation Program
    • 6.9.3. Thailand Production and Regulation
  • 6.10. Indonesia
    • 6.10.1. Vaccines in Indonesia
    • 6.10.2. Immunisation Program

7. Company Profiles

  • 7.1. Merck & Co., Inc. Overview
    • 7.1.1. Merck Financial Outlook
    • 7.1.2. Merck Product Portfolio
    • 7.1.3. Merck Strategic Developments
  • 7.2. Sanofi Overview
    • 7.2.1. Sanofi Financial Outlook
    • 7.2.2. Sanofi Product Portfolio
    • 7.2.3. Sanofi Strategic Developments
  • 7.3. Pfizer Overview
    • 7.3.1. Pfizer Financial Outlook
    • 7.3.2. Pfizer Product Portfolio
    • 7.3.3. Pfizer Strategic Developments
  • 7.4. GlaxoSmithKline PLC Overview
    • 7.4.1. GlaxoSmithKline PLC Financial Outlook
    • 7.4.2. GlaxoSmithKline PLC Product Portfolio
    • 7.4.3. GlaxoSmithKline PLC Strategic Developments
  • 7.5. Johnson & Johnson Overview
    • 7.5.1. Johnson & Johnson Financial Outlook
    • 7.5.2. Johnson & Johnson Product Portfolio
    • 7.5.3. Johnson & Johnson Strategic Developments
  • 7.6. AstraZeneca Overview
    • 7.6.1. AstraZeneca Financial Outlook
    • 7.6.2. AstraZeneca Product Portfolio
    • 7.6.3. AstraZeneca Strategic Developments
  • 7.7. Emergent BioSolutions, Inc.
    • 7.7.1. Emergent BioSolutions Financial Outlook
    • 7.7.2. Emergent BioSolutions Product Portfolio
    • 7.7.3. Emergent BioSolutions Strategic Developments
  • 7.8. CSL Ltd. Overview
    • 7.8.1. CSL Ltd. Financial Outlook
    • 7.8.2. CSL Ltd. Product Portfolio
    • 7.8.3. CSL Ltd. Strategic Developments
  • 7.9. Serum Institute of India Pvt. Ltd. Overview
    • 7.9.1. Serum Institute of India Pvt. Ltd. Financial Outlook
    • 7.9.2. Serum Institute of India Pvt. Ltd. Product Portfolio
    • 7.9.3. Serum Institute of India Pvt. Ltd. Strategic Developments
  • 7.10. Astellas Pharma Overview
    • 7.10.1. Astellas Pharma Financial Outlook
    • 7.10.2. Astellas Pharma Product Portfolio
    • 7.10.3. Astellas Pharma Strategic Developments
  • 7.11. Mitsubishi Tanabe Pharma Corporation Overview
    • 7.11.1. Mitsubishi Tanabe Pharma Corporation Financial Outlook
    • 7.11.2. Mitsubishi Tanabe Pharma Corporation Product Portfolio
    • 7.11.3. Mitsubishi Tanabe Pharma Corporation Strategic Developments
  • 7.12. Sun Pharmaceuticals Industries Ltd. Overview
    • 7.12.1. Sun Pharmaceutical Industries Ltd. Financial Outlook
    • 7.12.2. un Pharmaceutical Industries Ltd. Product Portfolio
    • 7.12.3. Sun Pharmaceutical Industries Ltd. Strategic Developments
  • 7.13. Takeda Pharmaceutical Company Limited Overview
    • 7.13.1. Takeda Pharmaceutical Company Limited, Financial Outlook
    • 7.13.2. Takeda Pharmaceutical Company Limited, Product Portfolio
    • 7.13.3. Takeda Pharmaceutical Company Limited. Strategic Developments

8. Conclusions

  • 8.1. Vaccines Market: Strong Growth Expected
  • 8.2. Asia Vaccines Market in 2018
    • 8.2.1. Current Leading Vaccine Technology Segments
    • 8.2.2. Current Leading Indication Segments
    • 8.2.3. Leading National and Regional Markets
  • 8.3. Asia Vaccines Market Forecast 2018-2029
  • 8.4. Pipeline Analysis
  • 8.5. New Vaccine Opportunities

Appendices

  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form